<p>/PRNewswire/ -- <strong>MetaVia Inc.</strong>（纳斯达克：MTVA）（MetaVia 或公司）是一家专注于转变心脏代谢疾病的临床阶段生物技术公司，今天宣布其之前宣布的 A 类单位和 B 类单位的承销公开发行已完成，预计总收益约为 930 万美元，未扣除承销折扣和佣金及发行费用，并且不包括任何未来可能来自认股权证行使的收益，其中包括承销商全额行使额外配售选项以购买额外股份和认股权证。</p>
<p>此次承销公开发行包括总计 3,005,574 股普通股（或普通股等值物）、4,508,361 份 C 系列认股权证和 4,508,361 份 D 系列认股权证，按每股普通股及随附的 C 系列和 D 系列认股权证的联合公开发行价格为 3.10 美元。C 系列认股权证可立即行使，行使价格为 3.10 美元，并在初始发行日期五周年时到期。D 系列认股权证可立即行使，行使价格为 3.10 美元，并在初始发行日期两周年时到期。D 系列认股权证在公司选择的情况下，可以在其 Phase 1b Part III 临床试验的积极数据发布后通过广泛传播的新闻稿进行赎回，前提是满足某些条件。本次发行的 C 系列和 D 系列认股权证为固定价格，不包含任何可变定价特征或替代行使条款。</p>
<p>如果完全以现金行使，预先资助的认股权证、C 系列普通认股权证和 D 系列普通认股权证可能产生约 2800 万美元的未来总收益。MetaVia 打算将承销公开发行的净收益用于营运资金和一般企业用途，包括继续开发 DA-1726 用于治疗肥胖。</p>
<p>Ladenburg Thalmann 6 Co. Inc.在此次承销公开发行中担任唯一的账簿管理人。</p>
<p>作为承销公开发行的一部分发行的证券是根据 S-1 表格的注册声明（文件编号 333-292581）提供的，该注册声明最初于 2026 年 1 月 5 日向美国证券交易委员会（&#34;SEC&#34;）提交，并于 2026 年 1 月 12 日进行了修订，并于 2026 年 1 月 15 日获得有效，以及根据规则 462(b) 提交的额外 S-1 表格注册声明，该注册声明于 2026 年 1 月 15 日提交并在提交时生效。最终招股说明书的副本可以在 SEC 的网站 www.sec.gov 上获取，或从 Ladenburg Thalmann 6 Co. Inc.的招股说明书部门获取，地址为 640 Fifth Avenue, 4th Floor, New York, New York 10019，或通过电子邮件发送至 [email protected]。</p>
<p>本新闻稿不构成出售要约或购买要约的征求，也不会在任何法律禁止注册或资格的司法管辖区内销售这些证券。</p>
<p><strong>关于 MetaVia</strong></p>
<p>MetaVia Inc.是一家专注于转变心脏代谢疾病的临床阶段生物技术公司。该公司目前正在开发 DA-1726 用于治疗肥胖，并正在开发 vanoglipel（DA-1241）用于治疗代谢功能障碍相关性脂肪肝炎（MASH）。DA-1726 是一种新型的胃抑制素（OXM）类似物，作为胰高血糖素样肽-1 受体（GLP1R）和胰高血糖素受体（GCGR）的双重激动剂。OXM 是一种自然发生的肠道激素，能够激活 GLP1R 和 GCGR，从而减少食物摄入并增加能量消耗，因此可能导致比选择性 GLP1R 激动剂更优越的体重减轻效果。在一项针对肥胖的 Phase 1 多次递增剂量（MAD）试验中，DA-1726 展示了最佳的减重、血糖控制和腰围减少的潜力。Vanoglipel（DA-1241）是一种新型的 G 蛋白偶联受体 119（GPR119）激动剂，促进关键肠道肽 GLP-1、GIP 和 PYY 的释放。在临床前研究中，vanoglipel（DA-1241）对肝脏炎症、脂质代谢、体重减轻和葡萄糖代谢产生了积极影响，减少了肝脏脂肪变性、肝脏炎症和肝纤维化，同时改善了血糖控制。在一项 Phase 2a 临床研究中，vanoglipel（DA-1241）展示了直接的肝脏作用以及其降糖效果。</p>
<p>欲了解更多信息，请访问 www.metaviatx.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中的某些声明可能被视为 1995 年《私人证券诉讼改革法案》所定义的前瞻性声明。诸如 “相信”、“期望”、“预期”、“可能”、“将”、“应该”、“寻求”、“大约”、“潜在”、“打算”、“项目”、“计划”、“估计” 或这些词的否定形式或其他类似术语（以及其他提及未来事件、条件或情况的词语或表达）旨在识别前瞻性声明，这些声明包括但不限于关于预计使用承销公开发行的净收益以及承销公开发行的潜在未来总收益的声明。前瞻性声明是关于未来事件的预测、展望和其他声明，这些声明基于当前的期望和假设，因此受到风险和不确定性的影响。许多因素可能导致实际未来事件与本新闻稿中的前瞻性声明存在重大差异，包括但不限于与 MetaVia 执行其商业战略的能力相关的风险；MetaVia 对其现有现金是否足以支持 MetaVia 运营的期望；监管提交的时间表；在 MetaVia 当前和未来产品候选者的开发步骤中获得监管批准的能力；实现与东亚 ST 有限公司的许可协议的利益的能力，包括对 MetaVia 未来财务和运营结果的影响；MetaVia 的合同制造商、临床研究合作伙伴及其他参与 MetaVia 当前和未来产品候选者开发的人员的合作；MetaVia 的产品候选者与用于治疗的任何其他产品之间的潜在负面相互作用；MetaVia 及时启动和完成临床试验的能力；MetaVia 招募临床试验受试者的能力；MetaVia 是否从其临床试验中获得与前临床和以前临床试验结果一致的结果；与许可协议相关的已知和未知成本的影响，包括与许可协议相关的任何诉讼或监管行动的成本；适用法律或法规变化的影响；MetaVia 股价变化对许可协议条款和任何未来融资的影响；以及 MetaVia 向证券交易委员会提交的文件中描述的其他风险和不确定性，包括 MetaVia 最近的 10-K 表格年度报告和随后的 10-Q 表格季度报告。前瞻性声明仅在作出时有效。MetaVia 不承担任何义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。</p>
<p><strong>联系方式：</strong></p>
<p><strong>MetaVia</strong> Marshall H. Woodworth</p>
<p>首席财务官</p>
<p>+1-857-299-1033</p>
<p>[email protected]</p>
<p><strong>Rx Communications Group</strong></p>
<p>Michael Miller</p>
<p>+1-917-633-6086</p>
<p>[email protected]</p>
<p>来源：MetaVia Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE2Jk5ld3NJdGVtSWQ9Tlk2NTI0OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTYxNjAxUFJfTkVXU19VU1BSX19fX19OWTY1MjQ4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE2Jk5ld3NJdGVtSWQ9Tlk2NTI0OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTYxNjAxUFJfTkVXU19VU1BSX19fX19OWTY1MjQ4"/></p>

MTVA

<p>MetaVia Inc. 成功完成了其承销的公开发行，筹集了约 930 万美元。此次发行包括 3,005,574 股普通股和认股权证，定价为每股 3.10 美元。筹集的资金将用于营运资金以及推进 DA-1726 的肥胖治疗临床开发。C 轮和 D 轮认股权证可立即行使，并具有特定的到期日期。Ladenburg Thalmann & Co. Inc. 担任此次发行的唯一账簿管理人</p>

<p>, /PRNewswire/ -- <strong>MetaVia Inc.</strong>(Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of Class A Units and Class B Units for gross proceeds of approximately $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants.</p>
<div class="lb-trans"><p>/PRNewswire/ -- <strong>MetaVia Inc.</strong>（纳斯达克：MTVA）（MetaVia 或公司）是一家专注于转变心脏代谢疾病的临床阶段生物技术公司，今天宣布其之前宣布的 A 类单位和 B 类单位的承销公开发行已完成，预计总收益约为 930 万美元，未扣除承销折扣和佣金及发行费用，并且不包括任何未来可能来自认股权证行使的收益，其中包括承销商全额行使额外配售选项以购买额外股份和认股权证。</p>
</div><p>The underwritten public offering comprised of an aggregate of 3,005,574 shares of common stock (or common stock equivalents), 4,508,361 Series C Warrants and 4,508,361 Series D Warrants priced at a combined public offering price of $3.10 per share of common stock and accompanying Series C Warrants and Series D Warrants. The Series C Warrants are immediately exercisable, have an exercise price of $3.10, and expire on the five year anniversary of the initial issuance date. The Series D Warrants are immediately exercisable, have an exercise price of $3.10, and expire on the two year anniversary of the initial issuance date. The Series D Warrants are callable at the Company's option following the release of a positive data readout for its Phase 1b Part III clinical trial for DA-1726 via a widely disseminated press release, subject to satisfaction of certain conditions. The Series C Warrants and Series D Warrants issued in this offering are fixed priced and do not contain any variable pricing features or alternative exercise provisions.</p>
<div class="lb-trans"><p>此次承销公开发行包括总计 3,005,574 股普通股（或普通股等值物）、4,508,361 份 C 系列认股权证和 4,508,361 份 D 系列认股权证，按每股普通股及随附的 C 系列和 D 系列认股权证的联合公开发行价格为 3.10 美元。C 系列认股权证可立即行使，行使价格为 3.10 美元，并在初始发行日期五周年时到期。D 系列认股权证可立即行使，行使价格为 3.10 美元，并在初始发行日期两周年时到期。D 系列认股权证在公司选择的情况下，可以在其 Phase 1b Part III 临床试验的积极数据发布后通过广泛传播的新闻稿进行赎回，前提是满足某些条件。本次发行的 C 系列和 D 系列认股权证为固定价格，不包含任何可变定价特征或替代行使条款。</p>
</div><p>If fully exercised for cash, the Pre-Funded Warrants, the Series C Common Warrants and the Series D Common Warrants could yield up to approximately $28.0 million in future gross proceeds. MetaVia intends to use the net proceeds from the underwritten public offering for working capital and general corporate purposes, including to continue the clinical development of DA-1726 for the treatment of obesity.</p>
<div class="lb-trans"><p>如果完全以现金行使，预先资助的认股权证、C 系列普通认股权证和 D 系列普通认股权证可能产生约 2800 万美元的未来总收益。MetaVia 打算将承销公开发行的净收益用于营运资金和一般企业用途，包括继续开发 DA-1726 用于治疗肥胖。</p>
</div><p>Ladenburg Thalmann &amp; Co. Inc. acted as sole book-running manager in connection with the underwritten public offering.</p>
<div class="lb-trans"><p>Ladenburg Thalmann 6 Co. Inc.在此次承销公开发行中担任唯一的账簿管理人。</p>
</div><p>The securities issued as part of the underwritten public offering were offered pursuant to a registration statement on Form S-1 (File No. 333-292581), which was initially filed with the U.S. Securities and Exchange Commission (&#34;SEC&#34;) on January 5, 2026, as amended on January 12, 2026, and declared effective on January 15, 2026 and an additional registration statement on Form S-1 filed pursuant to Rule 462(b), which was filed on January 15, 2026 and became effective upon filing. Copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from Ladenburg Thalmann &amp; Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at [email protected].</p>
<div class="lb-trans"><p>作为承销公开发行的一部分发行的证券是根据 S-1 表格的注册声明（文件编号 333-292581）提供的，该注册声明最初于 2026 年 1 月 5 日向美国证券交易委员会（&#34;SEC&#34;）提交，并于 2026 年 1 月 12 日进行了修订，并于 2026 年 1 月 15 日获得有效，以及根据规则 462(b) 提交的额外 S-1 表格注册声明，该注册声明于 2026 年 1 月 15 日提交并在提交时生效。最终招股说明书的副本可以在 SEC 的网站 www.sec.gov 上获取，或从 Ladenburg Thalmann 6 Co. Inc.的招股说明书部门获取，地址为 640 Fifth Avenue, 4th Floor, New York, New York 10019，或通过电子邮件发送至 [email protected]。</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的征求，也不会在任何法律禁止注册或资格的司法管辖区内销售这些证券。</p>
</div><p><strong>About MetaVia</strong></p>
<div class="lb-trans"><p><strong>关于 MetaVia</strong></p>
</div><p>MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel (DA-1241) is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel (DA-1241) demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel (DA-1241) demonstrated direct hepatic action in addition to its glucose lowering effects.</p>
<div class="lb-trans"><p>MetaVia Inc.是一家专注于转变心脏代谢疾病的临床阶段生物技术公司。该公司目前正在开发 DA-1726 用于治疗肥胖，并正在开发 vanoglipel（DA-1241）用于治疗代谢功能障碍相关性脂肪肝炎（MASH）。DA-1726 是一种新型的胃抑制素（OXM）类似物，作为胰高血糖素样肽-1 受体（GLP1R）和胰高血糖素受体（GCGR）的双重激动剂。OXM 是一种自然发生的肠道激素，能够激活 GLP1R 和 GCGR，从而减少食物摄入并增加能量消耗，因此可能导致比选择性 GLP1R 激动剂更优越的体重减轻效果。在一项针对肥胖的 Phase 1 多次递增剂量（MAD）试验中，DA-1726 展示了最佳的减重、血糖控制和腰围减少的潜力。Vanoglipel（DA-1241）是一种新型的 G 蛋白偶联受体 119（GPR119）激动剂，促进关键肠道肽 GLP-1、GIP 和 PYY 的释放。在临床前研究中，vanoglipel（DA-1241）对肝脏炎症、脂质代谢、体重减轻和葡萄糖代谢产生了积极影响，减少了肝脏脂肪变性、肝脏炎症和肝纤维化，同时改善了血糖控制。在一项 Phase 2a 临床研究中，vanoglipel（DA-1241）展示了直接的肝脏作用以及其降糖效果。</p>
</div><p>For more information, please visit www.metaviatx.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.metaviatx.com。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#34;believes&#34;, &#34;expects&#34;, &#34;anticipates&#34;, &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;seeks&#34;, &#34;approximately&#34;, &#34;potential&#34;, &#34;intends&#34;, &#34;projects&#34;, &#34;plans&#34;, &#34;estimates&#34; or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements, which include, among other statements, statements regarding the anticipated use of the net proceeds from the underwritten public offering and the potential future gross proceeds from the underwritten public offering. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's ability to execute on its commercial strategy; MetaVia's expectations regarding the sufficiency of its existing cash on hand to fund MetaVia's operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿中的某些声明可能被视为 1995 年《私人证券诉讼改革法案》所定义的前瞻性声明。诸如 “相信”、“期望”、“预期”、“可能”、“将”、“应该”、“寻求”、“大约”、“潜在”、“打算”、“项目”、“计划”、“估计” 或这些词的否定形式或其他类似术语（以及其他提及未来事件、条件或情况的词语或表达）旨在识别前瞻性声明，这些声明包括但不限于关于预计使用承销公开发行的净收益以及承销公开发行的潜在未来总收益的声明。前瞻性声明是关于未来事件的预测、展望和其他声明，这些声明基于当前的期望和假设，因此受到风险和不确定性的影响。许多因素可能导致实际未来事件与本新闻稿中的前瞻性声明存在重大差异，包括但不限于与 MetaVia 执行其商业战略的能力相关的风险；MetaVia 对其现有现金是否足以支持 MetaVia 运营的期望；监管提交的时间表；在 MetaVia 当前和未来产品候选者的开发步骤中获得监管批准的能力；实现与东亚 ST 有限公司的许可协议的利益的能力，包括对 MetaVia 未来财务和运营结果的影响；MetaVia 的合同制造商、临床研究合作伙伴及其他参与 MetaVia 当前和未来产品候选者开发的人员的合作；MetaVia 的产品候选者与用于治疗的任何其他产品之间的潜在负面相互作用；MetaVia 及时启动和完成临床试验的能力；MetaVia 招募临床试验受试者的能力；MetaVia 是否从其临床试验中获得与前临床和以前临床试验结果一致的结果；与许可协议相关的已知和未知成本的影响，包括与许可协议相关的任何诉讼或监管行动的成本；适用法律或法规变化的影响；MetaVia 股价变化对许可协议条款和任何未来融资的影响；以及 MetaVia 向证券交易委员会提交的文件中描述的其他风险和不确定性，包括 MetaVia 最近的 10-K 表格年度报告和随后的 10-Q 表格季度报告。前瞻性声明仅在作出时有效。MetaVia 不承担任何义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。</p>
</div><p><strong>Contacts:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>MetaVia</strong> Marshall H. Woodworth</p>
<div class="lb-trans"><p><strong>MetaVia</strong> Marshall H. Woodworth</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官</p>
</div><p>+1-857-299-1033</p>
<div class="lb-trans"><p>+1-857-299-1033</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p><strong>Rx Communications Group</strong></p>
<div class="lb-trans"><p><strong>Rx Communications Group</strong></p>
</div><p>Michael Miller</p>
<div class="lb-trans"><p>Michael Miller</p>
</div><p>+1-917-633-6086</p>
<div class="lb-trans"><p>+1-917-633-6086</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE MetaVia Inc.</p>
<div class="lb-trans"><p>来源：MetaVia Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE2Jk5ld3NJdGVtSWQ9Tlk2NTI0OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTYxNjAxUFJfTkVXU19VU1BSX19fX19OWTY1MjQ4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY65248&amp;Transmission_Id=202601161601PR_NEWS_USPR_____NY65248&amp;DateId=20260116"/></p>

MetaVia 宣布完成 930 万美元的包销公开发行，其中包括全额行使配售选择权